These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rifaximin for the treatment of irritable bowel syndrome. Cremonini F; Lembo A Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066 [TBL] [Abstract][Full Text] [Related]
23. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. Brigidi P; Swennen E; Rizzello F; Bozzolasco M; Matteuzzi D J Chemother; 2002 Jun; 14(3):290-5. PubMed ID: 12120885 [TBL] [Abstract][Full Text] [Related]
24. Use and safety of rifaximin in children with inflammatory bowel disease. Muniyappa P; Gulati R; Mohr F; Hupertz V J Pediatr Gastroenterol Nutr; 2009 Oct; 49(4):400-4. PubMed ID: 19668011 [TBL] [Abstract][Full Text] [Related]
25. Optimizing therapy for inflammatory bowel disease. Robinson M Am J Gastroenterol; 1997 Dec; 92(12 Suppl):12S-17S. PubMed ID: 9395347 [TBL] [Abstract][Full Text] [Related]
26. [Inflammatory bowel disease: an overview]. Herrlinger K Med Monatsschr Pharm; 2013 Nov; 36(11):402-8; quiz 409. PubMed ID: 24640117 [TBL] [Abstract][Full Text] [Related]
27. Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases. DuPont HL Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():1-2. PubMed ID: 26618920 [TBL] [Abstract][Full Text] [Related]
29. Probiotics for inflammatory bowel disease: a critical appraisal. Sans M Dig Dis; 2009; 27 Suppl 1():111-4. PubMed ID: 20203506 [TBL] [Abstract][Full Text] [Related]
30. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease. Szewczuk MR; Depew WT Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000 [TBL] [Abstract][Full Text] [Related]
31. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
32. Clinical usefulness of probiotics in inflammatory bowel diseases. Mach T J Physiol Pharmacol; 2006 Nov; 57 Suppl 9():23-33. PubMed ID: 17242485 [TBL] [Abstract][Full Text] [Related]
33. The role of anti(myco)bacterial interventions in the management of IBD: is there evidence at all? Pineton de Chambrun GP; Torres J; Darfeuille-Michaud A; Colombel JF Dig Dis; 2012; 30(4):358-67. PubMed ID: 22796797 [TBL] [Abstract][Full Text] [Related]
34. Antibacterial and antimycobacterial treatment for inflammatory bowel disease. Ohkusa T; Sato N J Gastroenterol Hepatol; 2005 Mar; 20(3):340-51. PubMed ID: 15740475 [TBL] [Abstract][Full Text] [Related]
35. Rifaximin for active ulcerative colitis. Guslandi M; Petrone MC; Testoni PA Inflamm Bowel Dis; 2006 Apr; 12(4):335. PubMed ID: 16633057 [No Abstract] [Full Text] [Related]
36. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Gionchetti P; Rizzello F; Ferrieri A; Venturi A; Brignola C; Ferretti M; Peruzzo S; Miglioli M; Campieri M Dig Dis Sci; 1999 Jun; 44(6):1220-1. PubMed ID: 10389700 [No Abstract] [Full Text] [Related]
39. Use of antibiotics in the treatment of inflammatory bowel disease. Perencevich M; Burakoff R Inflamm Bowel Dis; 2006 Jul; 12(7):651-64. PubMed ID: 16804403 [TBL] [Abstract][Full Text] [Related]